Abstract:<div class="abstract-group"> <section class="article-section article-section__abstract" lang="en" data-lang="en" id="section-1-en"> <h3 class="article-section__header main abstractlang_en main">Abstract</h3> <div class="article-section__content en main"> <p>Calcium‐activated chloride channels (CaCCs) are ion channels with key roles in physiological processes. They are abnormally expressed in various cancers, including esophageal squamous cell cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastrointestinal stromal tumors. The CaCC component TMEM16A/ANO1 was recently shown to be overexpressed in lung adenocarcinoma cells and may serve as a tumorigenic protein. In this study, we determined that matrine is a potent TMEM16A inhibitor that exerts anti‐lung adenocarcinoma effects. Patch clamp experiments showed that matrine inhibited TMEM16A current in a concentration‐dependent manner with an IC<sub>50</sub> of 27.94 ± 4.78 μM. Molecular simulation and site‐directed mutation experiments demonstrated that the matrine‐sensitive sites of the TMEM16A channel involve the amino acids Y355, F411, and F415. Results of cell viability and wound healing assays showed that matrine significantly inhibited the proliferation and migration of LA795 cells, which exhibit high TMEM16A expression. In contrast, matrine has only weak inhibitory effect on CCD‐19Lu and HeLa cells lacking TMEM16A expression. Matrine‐induced effects on the proliferation and migration of LA795 cells were abrogated upon shRNA‐mediated TMEM16A knockdown in LA795 cells. Finally, in vivo experiments demonstrated that matrine dramatically inhibited the growth of lung adenocarcinoma xenograft tumors in mice but did not affect mouse body weight. Collectively, these data indicate that matrine is an effective and safe TMEM16A inhibitor and that TMEM16A is the target of matrine anti‐lung adenocarcinoma activity. These findings provide new insight for the development of novel treatments for lung adenocarcinoma. </p>

Identification of Annexin A2 As a Target Protein for Plant Alkaloid Matrine

Matrine Induces Caspase-Dependent Apoptosis in Human Osteosarcoma Cells in Vitro and in Vivo Through the Upregulation of Bax and Fas/FasL and Downregulation of Bcl-2

Toxic Markers of Matrine Determined Using (1) H-NMR-Based Metabolomics in Cultured Cells In Vitro and Rats In Vivo.

Toxic Markers Of Matrine Determined Using H-1-Nmr-Based Metabolomics In Cultured Cells In Vitro And Rats In Vivo

Matrine: A Promising Natural Product With Various Pharmacological Activities

Research progress of matrine's anticancer activity and its molecular mechanism

Matrine Inhibits Invasiveness and Metastasis of Human Malignant Melanoma Cell Line A375 in Vitro

Matrine alkaloids modulating DNA damage repair in chemoresistant non-small cell lung cancer cells

Inhibitory effect of matrine on the in vitro invasiveness of human malignant melanoma cell line A375

Matrine inhibits the growth of natural killer/T-cell lymphoma cells by modulating CaMKIIγ-c-Myc signaling pathway

[Inhibition of invasiveness and expression of heparanase-mRNA in human malignant melanoma cell line A375 by matrine].

Effects of Matrine on the Proliferation and Apoptosis Induction in Human Malignant Melanoma Cell Line A375

Matrine is Identified As a Novel Macropinocytosis Inducer by a Network Target Approach

Matrine involves in the progression of gastric cancer through inhibiting miR-93-5p and upregulating the expression of target gene AHNAK

Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathway

Molecular Mechanism of Matrine from Sophora alopecuroides in the Reversing Effect of Multi-Anticancer Drug Resistance in K562/ADR Cells

Research Advances on Matrine

Synthesis, characterization and in vitro biological evaluation of two matrine derivatives

Inhibition of Matrine Against Gastric Cancer Cell Line MNK45 Growth and Its Anti-Tumor Mechanism

Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects

MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway